Intellectual Property - November 10, 2016
Modus Therapeutics announces two new U.S. patents
Modus Therapeutics has been granted two patents in the US covering its proprietary compound sevuparin. More specifically the two patents have been granted claims for the substance sevuparin per se and a manufacturing method for producing sevuparin (U.S. Patent no. 9,480,701) as well as its use in e.g. Sickle Cell Disease (U.S. Patent No. 9.480,702). […]
Intellectual Property - October 26, 2016
Dilaforette change name and announces IPO
Dilaforette Holding AB, a clinical-stage drug development and Karolinska Development portfolio company, announces its name change to Modus Therapeutics Holding AB and its intention to undertake an Initial Public Offering (IPO). A rights issue is planned in connection with the IPO in order to finance the further clinical development of the company’s lead candidate sevuparin for […]